Zusammenfassung
Antikoagulantien und Thrombozytenaggregationshemmer werden in steigendem Umfang bei Thrombosen, Embolien und arteriellen Gefäßkrankheiten mit unterschiedlichen therapeutischen Schwerpunkten eingesetzt. Die akute Antikoagulation mit Heparin und die nachfolgende Gabe oraler Vitamin-K-Antagonisten ist die Standard-therapie für akute Venenthrombosen und Lungenembolien. Daneben werden orale Antikoagulantien zur Prophylaxe kardiogener Hirnembolien bei atrialen Thromben und bei arteriosklerotisch bedingten Karotisstenosen angewendet. Auch niedermolekulare Heparine werden zunehmend für die Therapie tiefer Venenthrombosen bei ambulanten Patienten sowie für die ambulante Thromboseprophylaxe bei immobilisierten Patienten eingesetzt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Antiplatelet Trialists’ Collaboration (1994): Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit. Med. J. 308: 81–106.
Bousser M.G., Eschwege E., Haguenau M., Lefauconnier J.M., Thibult N. et al. (1983): “AICLA„ controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14: 5–14.
CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.
Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143: 1–13.
Enserink M. (1996): Fraud and ethics charges hit stroke drug trial. Seience 274: 2004–2005.
Gent M., Blakely J.A., Easton J.D., Ellis D.J., Hachinski V.C. et al. (1989): The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet I: 1215–1220.
Hass W.K., Easton J.D., Adams H.P. Jr., Pryse-Phillips W., Molony B.A. et al. (1989): A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. 321: 501–507.
Hirsh J., Levine M.N. (1992): Low molecular weight heparin. Blood 79: 1–17.
Klimt C.R., Knatterud G.L., Stamler J., Meier P. (1986): Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J. Am. Coll. Cardiol. 7: 251–269.
Kock H.-J., Schmit-Neuerburg K.P., Hanke J., Rudofsky G., Hirche H. (1995): Thromboprophylaxis with low-molecular-weight heparin in outpatients with pIaster-cast immobilisation of the leg. Lance 346: 459–461.
Koopman M.M.W., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P.M. et al. (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecularweight heparin administered at horne. N. Engl. J. Med. 334: 682–687.
Leizorovicz A., Haugh M.C., Chapuis F.-R., Samama M.M., Boissel J.-P. (1992): Low molecular weight heparin in prevention of perioperative thrombosis. Brit. Med. J. 305: 913–920.
Lensing A.W.A., Prins M.H., Davidson B.L., Hirsh J. (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch. Intern. Med. 155: 601–607.
Levine M., Gent M., Hirsh J., Leclerc J., Anderson D. et al. (1996): A comparison of low-molecular-weight heparin administered primarily at horne with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 334: 677–681.
The Persantine-Aspirin Reinfaction Study Research Group (1980): Persantine and aspirin in coronary heart disease. Circulation 62: 449–461.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2000). Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 1999. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57215-9_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-57215-9_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-66376-8
Online ISBN: 978-3-642-57215-9
eBook Packages: Springer Book Archive